Get the Stockscreener App
8.46
2.76%
-0.24
After Hours:
8.40
-0.06
-0.71%
Akari Therapeutics Plc Adr stock is traded at $8.46, with a volume of 52,713.
It is down -2.76% in the last 24 hours and down -21.16% over the past month.
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.
See More
Previous Close:
$8.70
Open:
$8.62
24h Volume:
52,713
Relative Volume:
0.08
Market Cap:
$14.81M
Revenue:
-
Net Income/Loss:
$-28.00M
P/E Ratio:
-0.427
EPS:
-19.8108
Net Cash Flow:
$-10.93M
1W Performance:
-20.64%
1M Performance:
-21.16%
6M Performance:
-22.95%
1Y Performance:
-81.12%
1-Day Range:
$8.08
$9.535
1-Week Range:
$8.08
$12.44
52-Week Range:
$3.015
$49.60
Akari Therapeutics Plc Adr Stock (AKTX) Company Profile
Name
Akari Therapeutics Plc Adr
Sector
Industry
Phone
(929) 274-7510
Address
401 EAST JACKSON STREET, TAMPA
Compare AKTX vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AKTX
Akari Therapeutics Plc Adr
|
8.46 | 15.23M | 0 | -28.00M | -10.93M | -19.81 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Akari Therapeutics Plc Adr Stock (AKTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-08-26 | Downgrade | Maxim Group | Buy → Hold |
| Jan-05-26 | Initiated | Ladenburg Thalmann | Buy |
| Jul-18-25 | Initiated | Maxim Group | Buy |
| Jan-04-19 | Upgrade | B. Riley FBR | Neutral → Buy |
| Feb-08-18 | Initiated | B. Riley FBR, Inc. | Neutral |
| Sep-22-17 | Upgrade | William Blair | Mkt Perform → Outperform |
| May-31-17 | Upgrade | Chardan Capital Markets | Sell → Neutral |
| Apr-17-17 | Reiterated | Chardan Capital Markets | Sell |
| Jul-11-16 | Initiated | Chardan Capital Markets | Sell |
View All
Akari Therapeutics Plc Adr Stock (AKTX) Latest News
Akari Therapeutics Plc Sponsored ADR Revenue Breakdown – LS:A4270Y - TradingView
Stock Ratings | Morgan Stanley raised its target price for Intel (INTC) to $75; Maxim Group initiated coverage on Rein Therapeutics (RNTX) with a target price of $4, representing a potential gain of 373.93%. - Sahm
Akari Therapeutics CEO Explains Why Growing Industry Demand for Next-Generation ADC Payloads Positions the Company at the Center of a Major Oncology Opportunity - Sahm
Akari Therapeutics partners with Whitehawk on dual payload study By Investing.com - Investing.com South Africa
Akari Therapeutics partners with Whitehawk on dual payload study - Investing.com
Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics - Sahm
Price to earnings forward of Akari Therapeutics Plc Sponsored ADR – TRADEGATE:CLA1 - TradingView
Form S-3/A Akari Therapeutics PLC For: 10 July By Investing.com - Investing.com South Africa
Akari Therapeutics (NASDAQ: AKTX) files to register 5.99M ADSs from May 2026 private placement - Stock Titan
Akari Therapeutics (NASDAQ: AKTX) adds private‑placement warrants and purchase agreement exhibits - Stock Titan
Akari Therapeutics Appoints Former AACR President and Renowned Oncology Drug Development Leader, Patricia LoRusso, D.O., to Scientific Advisory Board - Finviz
Akari Therapeutics appoints Patricia LoRusso to advisory board - Investing.com
Akari Therapeutics appoints Patricia LoRusso to advisory board By Investing.com - Investing.com India
Akari Therapeutics (NASDAQ: AKTX) registers 5,999,999 ADSs, 80,000-shares each - Stock Titan
Akari Therapeutics completes $8.3m capital raise in Q2 - Investing.com
Akari Therapeutics completes $8.3m capital raise in Q2 By Investing.com - Investing.com India
AKTXAkari Therapeutics Plc ADR Options - Finviz
Form S-1/A Akari Therapeutics PLC For: 26 June By Investing.com - Investing.com South Africa
White Lion resale of 2.5M Akari (NASDAQ: AKTX) ADSs under $25M equity deal - Stock Titan
AKTX Forecast — Price Target — Prediction for 2027 - TradingView
Akari Therapeutics Plc Sponsored ADR Actuals & Estimates (NASDAQ:AKTX) - TradingView
CLA1 Forecast — Price Target — Prediction for 2027 - TradingView
Form 4 Akari Therapeutics PLC For: 25 June By Investing.com - Investing.com India
Akari Therapeutics (AKTX) CEO granted stock options tied to ADS and financings - Stock Titan
Akari Therapeutics (AKTX) interim CFO granted new ADS awards - Stock Titan
A4270Y Forecast — Price Target — Prediction for 2027 - TradingView
AKTX Options Chain — NASDAQ:AKTX - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Akari Therapeutics PLC (FRA:CLA1) Valuation - GuruFocus
VNET Group, Akari Therapeutics and other big stocks moving lower in Tuesday's pre-market session - MSN
Akari Therapeutics Q1 2026 Earnings: EPS Misses Estimates but Stock Rises 5.7% on Pipeline HopeSurprise Factor Analysis - dars.gov.et
Large share issuance and governance votes ahead at Akari (NASDAQ: AKTX) 2026 AGM - Stock Titan
Akari Therapeutics partners with WuXi XDC on ADC development - Investing.com
Diluted earnings per share (diluted EPS) of Akari Therapeutics Plc Sponsored ADR – TRADEGATE:CLA1 - TradingView
12 Health Care Stocks Moving In Friday's Intraday Session - Sahm
Which stocks have an unusual volume on Thursday? - ChartMill
VNET Group, Akari Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Akari Therapeutics Soars as KRAS ADC Data Triggers Rerating - timothysykes.com
Akari Therapeutics (AKTX) AGM June 30, 2026 — equity authorizations, warrants/ADSs - Stock Titan
Akari Therapeutics (NASDAQ: AKTX) sets $5.5M ADS and warrant private placement - Stock Titan
Keep an eye on the top gainers and losers in Friday's session. - ChartMill
Friday's session: gap up and gap down stocks - ChartMill
Discover the top movers in Friday's pre-market session. - ChartMill
Akari Therapeutics Announces $5.5 Million Private Placement Offering - Sahm
Akari Therapeutics stock rockets 50% higher on KRAS combination data - Investing.com
Akari Therapeutics prices $5.5 million private placement By Investing.com - Investing.com South Africa
Akari Therapeutics prices $5.5 million private placement - Investing.com
Why Akari Therapeutics Stock Is Surging On Thursday? - Sahm
12 Health Care Stocks Moving In Tuesday's After-Market Session - Sahm
Akari Therapeutics secures European patent for ADC payload - Investing.com
Akari Therapeutics Plc Adr Stock (AKTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):